Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review.
Abstract
321 Background: G3 NENs are aggressive, and optimal systemic treatment is unclear. Temozolomide (TEM)-based regimens have been used to treat grade 1-2 NETs, but their efficacy in G3 NENs (Ki-67 > 20%) remains undetermined. Aims: To assess the clinical efficacy of TEM-containing regimens in advanced grade III gastroenteropancreatic NENs (GEPNENs). Methods: A multicentre retrospective review (2008-2017) of patients with metastatic/unresectable...
Paper Details
Title
Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review.
Published Date
Feb 1, 2019
Journal
Volume
37
Issue
4_suppl
Pages
321 - 321
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History